文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

COVID-19大流行期间观察性转化研究项目的见解:四年经验

Insights from an observational translational research program during the COVID-19 pandemic: Four years of experience.
PubMed 文献 · Vaccine · 2024-09-05

波士顿贝斯以色列女执事医疗中心于2020年启动COVID-19生物样本库,2020年4月至2024年7月共纳入1018名参与者并采集数千份生物样本,涵盖普通人群及免疫抑制、妊娠和哺乳期等临床试验中代表性不足的人群。该观察性研究适应大流行快速变化,实时生成关于COVID-19疫苗应答、混合免疫、免疫逃逸和免疫印记的数据,并通过预印本、同行评议论文和公共传播快速分享以用于公共卫生和疫苗政策。

要点

  • 2020年4月至2024年7月共纳入1018名参与者并采集数千份生物样本。
  • 纳入普通人群及免疫抑制、妊娠和哺乳期等临床试验中代表性不足的人群。
  • 团队合作、协作和灵活性是该项目成功的关键因素。

核心结论

  • 团队合作、协作和灵活性是该项目成功的关键因素,该项目实时生成了关于COVID-19疫苗应答、混合免疫、免疫逃逸和免疫印记的数据。

研究设计与样本

  • 观察性转化研究项目,2020年4月至2024年7月在波士顿贝斯以色列女执事医疗中心纳入1018名参与者并采集数千份生物样本。

主要发现

  • 该项目生成了关于多种人群COVID-19疫苗应答、突破感染后混合免疫、新发变异株免疫逃逸和加强免疫后免疫印记的实时数据。

临床怎么用

  • 通过预印本、同行评议论文和公共传播快速分享数据,使研究结果得以实时用于应对公共卫生问题并为疫苗政策提供信息。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The COVID-19 Biorepository at Beth Israel Deaconess Medical Center in Boston was initiated in 2020 to address questions about COVID-19 infection and vaccination in a time of urgent need. From April 2020 through July 2024, we enrolled 1018 participants and collected thousands of biospecimens. We enrolled participants from the general population as well as from specific populations that were not well represented in clinical trials, including immunosuppressed, pregnant, and lactating individuals. Our observational study was designed to accommodate the rapidly changing landscape of the pandemic, including the introduction of new vaccines and boosters, breakthrough infections, and emerging variants. Reflecting on the past four years of this experience, we believe that teamwork, collaboration, and flexibility were key factors for the success of this effort, which generated data in real time about COVID-19 vaccine responses in multiple populations, hybrid immunity following breakthrough infections, immune evasion of emerging variants, and immune imprinting following booster immunizations. Rapid dissemination of data through preprints, peer-reviewed publications, and public communications allowed for the real time use of our findings to address public health issues and to inform vaccine policies. The dedication of the study participants, clinical investigators, and laboratory investigators made this research program possible.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rowe M, Collier AY, Barouch DH, et al. Insights from an observational translational research program during the COVID-19 pandemic: Four years of experience. Vaccine. 2024. PMID: 39241351. doi:10.1016/j.vaccine.2024.126306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。